Deutsche Bank
VNDA icon

Deutsche Bank’s Vanda Pharmaceuticals VNDA Stock Holding History

Deutsche Bank’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,000
Closed -$1K – 5716
2013
Q3 		$1K Buy
+1,000
New +$10.7K ﹤0.01% 5450

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's VNDA Position: Q2 2026 in Review

Deutsche Bank reduced its Vanda Pharmaceuticals (VNDA) stake by 8.7% in Q2 2026, selling an estimated $32.8K and leaving 52,546 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #3008.

Deutsche Bank first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.2M in Q2 2019. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Deutsche Bank held 52,546 shares of Vanda Pharmaceuticals worth $322K as of Q2 2026.
  • Deutsche Bank sold 5,027 Vanda Pharmaceuticals shares in Q2 2026, an estimated $32.8K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3008 holding.
  • Deutsche Bank first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Deutsche Bank's Vanda Pharmaceuticals position peaked at $10.2M in Q2 2019.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.